Gubra to get up to 240 million euros in new Boehringer deal

29 May 2019

German pharma major Boehringer Ingelheim and Danish biotech Gubra have announced a second collaboration and license agreement for the development of new poly-agonist peptides to treat obesity.

This second joint research and development program involving the privately-held companies builds on an ongoing collaboration in the obesity field which was launched in 2017 and which has already achieved certain milestones set at the outset.

As part of the new deal, Gubra could receive up to 240 million euros ($267 million) in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK